TopoGEN products (Top2a) were used in the following study published in Nature. This is a very exciting and powerful result suggesting novel inroads to addressing the problem of cardiotoxicity.
In this work, authors develop obex inhibitors that target a distinct binding pocket in the ATPase domain of Topoisomerase II. They demonstrate how Topobexin, a Topoisomerase IIβ – selective catalytic inhibitor, blocks conformational changes and protects against anthracycline cardiotoxicity.
Let us know how we can help you with your drug development R&D when designing testing and validating novel topo drugs! We are a group of experienced investigators in the topo field and a reliable CRO.